Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic,...

Area of Science:

• Oncology
• Computational Biology
• Pharmacology

Background:

• Castration-resistant prostate cancer (CRPC) represents an advanced stage of prostate cancer with significant unmet therapeutic needs.
• Current treatment options for CRPC are limited, necessitating the exploration of novel therapeutic strategies.
• Identifying effective multitargeted agents is crucial for improving patient outcomes.

Purpose of the Study:

• To utilize a systems-based modeling approach, kinome regularization (KiR), for the identification of novel multitargeted kinase inhibitors (KIs) against CRPC.
• To evaluate the efficacy of predicted KIs, PP121 and SC-1, in preclinical models of CRPC, including bone microenvironments.
• To assess the potential of combining KIs with docetaxel as a therapeutic strategy for advanced CRPC.

Main Methods:

• Application of kinome regularization (KiR) for the in silico identification of multitargeted kinase inhibitors.
• In vitro 2D cell culture and in vivo subcutaneous xenograft models to assess KI efficacy.
• Ex vivo bone mimetic environment and in vivo tibia xenograft models to evaluate bone metastasis and resistance.
• Combination therapy studies involving KIs (PP121, SC-1) and docetaxel in vivo.

Main Results:

• Two identified KIs, PP121 and SC-1, demonstrated efficacy in suppressing CRPC growth in vitro and in subcutaneous xenografts.
• Resistance to PP121 and SC-1 was observed in bone microenvironments, both ex vivo and in vivo.
• Combination therapy of PP121 or SC-1 with docetaxel significantly inhibited tibia tumor growth, reduced growth factor signaling, and extended survival in vivo.
• Docetaxel monotherapy showed less efficacy compared to the combination treatments.

Conclusions:

• Computational modeling, specifically KiR, is a valuable tool for predicting physiologically relevant therapeutic strategies.
• Multitargeted kinase inhibitors show potential as chemosensitizers, enhancing the efficacy of standard chemotherapy in late-stage, metastatic CRPC.
• Combining novel kinase inhibitors with docetaxel offers a promising therapeutic approach to overcome resistance and improve outcomes in CRPC, particularly in bone metastases.